PHASE III LINC 3 STUDY DEMONSTRATES THAT ISTURISA® (OSILODROSTAT) IMPROVES PHYSICAL FEATURES ASSOCIATED WITH HYPERCORTISOLISM IN PATIENTS WITH CUSHING’S DISEASE 05/13/2022 RECORDATI RARE DISEASES ANNOUNCES MULTIPLE SCIENTIFIC ABSTRACTS TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY 05/10/2022 RECORDATI RARE DISEASES ANNOUNCE PUBLICATION IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM OF THE PHASE III LINC 4 STUDY CONFIRMING EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN PATIENTS WITH CUSHING’S DISEASE 03/29/2022 Pagination First page « First Previous page ‹ Previous … Page 2 Current page 3 Page 4 Page 5 … Next page Next › Last page Last »
PHASE III LINC 3 STUDY DEMONSTRATES THAT ISTURISA® (OSILODROSTAT) IMPROVES PHYSICAL FEATURES ASSOCIATED WITH HYPERCORTISOLISM IN PATIENTS WITH CUSHING’S DISEASE 05/13/2022
RECORDATI RARE DISEASES ANNOUNCES MULTIPLE SCIENTIFIC ABSTRACTS TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY 05/10/2022
RECORDATI RARE DISEASES ANNOUNCE PUBLICATION IN THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM OF THE PHASE III LINC 4 STUDY CONFIRMING EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN PATIENTS WITH CUSHING’S DISEASE 03/29/2022
